Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women
Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women
复制标题
DOI：
10.1158/1055-9965.epi-13-0944
复制
发表时间：
2014-05-01
影响因子：
3.8
通讯作者：
Li, Christopher I.
中科院分区：
文献类型：
--
作者：
Beaber, Elisabeth F.;Malone, Kathleen E.;Li, Christopher I.
背景：有证据表明，最近口服避孕药(OC)的使用与乳腺癌风险的小幅增加有关；然而，与当代OC制剂和分子亚型相关的风险尚未得到很好的表征。方法：我们从2004年到2010年对居住在西雅图-普吉特海湾地区的20-44岁女性进行了一项基于人群的浸润性乳腺癌病例对照研究(985例病例和882例对照)。我们通过面对面访谈收集了有关避孕用具使用和参与者特征的信息。多变量调整后的Logistic回归用于计算优势比(OR)和95%可信区间(CI)。结果：终身使用OC的年限为15年与乳腺癌风险增加相关(OR为1.5；95%CI为1.1-2.2)。当前使用OC(在参考日期的1年内)=5年与风险增加相关(OR，1.6；95%CI，1.1-2.5)，并且OC准备的风险没有统计学上的显著差异。在20岁到39岁的女性中，雌激素受体阴性(ER-)和三阴性乳腺癌(目前使用>；=5年，年龄20-39岁：ER-OR，3.5；95%CI，1.3-9.0；三阴性OR，3.7；95%CI，1.2-11.8)的风险普遍较大，尽管组间差异不具有统计学意义。结论：长期使用当代OCS和当前使用>；=5年与20-44岁女性乳腺癌风险的增加有关。年轻女性和ER和三阴性乳腺癌的风险可能更大，但这些发现需要证实。影响：随着OC准备的发展，需要继续监测和按分子亚型合并分析OC的使用和乳腺癌风险。(C)2014年AACR。
Background: Evidence suggests that recent oral contraceptive (OC) use is associated with a small increased breast cancer risk; yet risks associated with contemporary OC preparations and by molecular subtype are not well characterized.Methods: We conducted a population-based case-control study of invasive breast cancer among women ages 20 to 44 residing in the Seattle-Puget Sound area from 2004 to 2010 (985 cases and 882 controls). We collected information on contraceptive use and participant characteristics via an in-person interview. Multivariable- adjusted logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI).Results: Lifetime duration of OC use for >= 15 years was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.1-2.2). Current OC use (within 1 year of reference date) for >= 5 years was associated with an increased risk (OR, 1.6; 95% CI, 1.1-2.5) and there were no statistically significant differences in risk by OC preparation. Risk magnitudes were generally greater among women ages 20 to 39, and for estrogen receptor-negative (ER-) and triple-negative breast cancer (current use for >= 5 years among ages 20-39: ER- OR, 3.5; 95% CI, 1.3-9.0; triple-negative OR, 3.7; 95% CI, 1.2-11.8), although differences between groups were not statistically significant.Conclusions: Long-term use of contemporary OCs and current use for >= 5 years was associated with an increased breast cancer risk among women ages 20 to 44. Risk may be greater among younger women and for ER- and triple-negative breast cancer, but these findings require confirmation.Impact: Continued surveillance and pooled analyses of OC use and breast cancer risk by molecular subtype are needed as OC preparations evolve. (C) 2014 AACR.